Prothena - Stock Price History | PRTA

Historical daily share price chart and data for Prothena since 2023 adjusted for splits. The latest closing stock price for Prothena as of January 27, 2023 is 57.12.
  • The all-time high Prothena stock closing price was 78.89 on September 23, 2021.
  • The Prothena 52-week high stock price is 66.47, which is 16.4% above the current share price.
  • The Prothena 52-week low stock price is 21.06, which is 63.1% below the current share price.
  • The average Prothena stock price for the last 52 weeks is 40.05.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Prothena Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 38.8881 49.2200 65.0000 22.7300 60.2500 21.96%
2021 42.2095 12.3000 78.8900 11.0000 49.4000 311.32%
2020 11.7699 15.6300 15.7700 7.5400 12.0100 -24.13%
2019 10.5694 10.5000 17.0100 6.8900 15.8300 53.69%
2018 20.4841 37.8000 45.0400 8.7300 10.3000 -72.53%
2017 54.5062 49.7900 67.7500 35.4400 37.4900 -23.79%
2016 47.9551 62.2200 67.6400 30.1200 49.1900 -27.78%
2015 46.1863 20.3500 75.3100 19.0500 68.1100 228.08%
2014 24.7390 28.1000 48.3000 17.2600 20.7600 -21.72%
2013 14.7389 7.0000 29.0400 5.8400 26.5200 261.80%
2012 6.9833 7.2000 7.3300 6.8000 7.3300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.702B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00